Sai Life Sciences , a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has marked a significant milestone in its growth strategy with the inauguration of a new dedicated facility for veterinary API production. The company officially opened Unit VI on September 18, 2025, in Bidar, India, strategically located alongside its flagship API manufacturing site, Unit IV.

Expansion into Veterinary APIs

The new Unit VI facility represents Sai Life Sciences' strategic move into the burgeoning veterinary pharmaceutical market. Designed to meet stringent safety, sustainability, and regulatory compliance standards, the facility aims to produce high-quality APIs for veterinary applications. This expansion positions the company to offer efficient and scalable manufacturing solutions to leading global animal health companies.

Strategic Location and Capabilities

Situated adjacent to the company's existing Unit IV in Bidar, Karnataka, the new facility leverages Sai Life Sciences' established infrastructure and expertise. The strategic location allows for operational synergies and streamlined processes, enhancing the company's overall manufacturing capabilities.

Meeting Growing Demand

Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, emphasized the significance of this investment, stating, "This investment strengthens our ability to meet the growing global demand for high-quality veterinary pharmaceuticals while ensuring the highest standards of innovation, efficiency, and sustainability. We are proud to support our innovator partners in their mission of offering reliable solutions that enhance animal well-being."

Advanced Technologies and Compliance

Unit VI incorporates advanced technologies, robust supply chain management, and best-in-class safety practices. These features ensure reliable and cost-effective manufacturing of animal health APIs, aligning with the company's reputation for advanced process capabilities, operational excellence, and stringent quality standards.

Market Opportunity

The expansion into veterinary APIs comes at a time when the market presents significant growth opportunities. Increasing demand for veterinary medicines and advancements in animal healthcare are driving this sector's growth. Sai Life Sciences' investment in this specialized facility aligns with its strategic vision to enhance its offerings in niche, high-value segments of the pharmaceutical industry.

Company Profile

With over two decades of manufacturing expertise, Sai Life Sciences has established itself as a trusted partner in API production. The company works with over 300 global innovator pharma and biotech companies, accelerating the discovery, development, and commercialization of NCE small molecule programs. Sai Life Sciences employs over 3,400 people across its facilities in India, UK, and USA.

Investor Relations

In a related development, Sai Life Sciences has scheduled meetings with several prominent investment firms on September 24, 2025. The company will engage with representatives from William Blair Investment Management, Orbimed Advisors India, Dymon Asia, Norges Bank Investment Management, and Amansa Capital in Hyderabad. This engagement with investors underscores the company's commitment to transparency and its growing profile in the global pharmaceutical industry.

As Sai Life Sciences continues to expand its capabilities and market reach, the new veterinary API facility in Bidar marks a significant step in the company's journey to becoming a comprehensive partner for the global pharmaceutical industry, now extending its expertise into the animal health sector.

Sai Life Sciences , a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a significant expansion of its production capabilities at its flagship API manufacturing facility in Bidar, India. The company has successfully completed Phase II of its Production Block 11 (PB-11), marking a substantial increase in its manufacturing capacity.

Expansion Details

The completion of Phase II adds approximately 91 KL to the existing capacity of Production Block 11. This expansion brings the total capacity of PB-11 to around 200 KL, making it the single largest reactor volume block at the Bidar site. As a result of this development, Sai Life Sciences has boosted its total installed reactor capacity at the Bidar facility to 700 KL.

Strategic Importance

Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, emphasized the strategic importance of this expansion, stating, "This expansion at Bidar is more than additional capacity — it is about giving our partners the confidence that we can scale with their needs, deliver reliably, and adapt to the increasing complexity of their programs."

Facility Highlights

The Bidar facility, known as Unit IV, is Sai Life Sciences' flagship manufacturing site. It specializes in the production of APIs (Active Pharmaceutical Ingredients) and advanced intermediates for highly regulated markets, including the United States, European Union, and Japan. Key features of the facility include:

• 12 production blocks with a combined capacity of 700 KL
• Dedicated facilities for high-potency APIs (HPAPIs)
• State-of-the-art QC laboratories ensuring compliance and product integrity
• Advanced capabilities such as lyophilization, cryogenic reactions, high-pressure reactions, and commercial-scale chromatography

Regulatory Compliance and Quality Assurance

The Bidar facility has successfully passed inspections and received approvals from leading global regulatory agencies, including the USFDA, PMDA (Japan), and CDSCO (India). Sai Life Sciences' commitment to quality and compliance is further evidenced by the fact that its manufacturing units had undergone over 75 customer audits in the preceding three years.

Company Overview

Sai Life Sciences has established itself as a key player in the pharmaceutical industry, working with over 300 global innovator pharma and biotech companies. The company's focus is on accelerating the discovery, development, and commercialization of NCE (New Chemical Entity) small molecule programs. With a workforce of over 3,400 employees across facilities in India, the UK, and the USA, Sai Life Sciences continues to strengthen its position in the global pharmaceutical manufacturing landscape.

This expansion reinforces Sai Life Sciences' commitment to meeting the growing demands of its clients and further solidifies its role in the pharmaceutical supply chain, enabling faster and more reliable delivery of critical APIs and intermediates to global markets.